Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SWI/SNF Complex Alterations in Tumors with Rhabdoid Features: Novel Therapeutic Approaches and Opportunities for Adoptive Cell Therapy.
Soto-Castillo JJ, Llavata-Marti L, Fort-Culillas R, Andreu-Cobo P, Moreno R, Codony C, García Del Muro X, Alemany R, Piulats JM, Martin-Liberal J. Soto-Castillo JJ, et al. Among authors: martin liberal j. Int J Mol Sci. 2023 Jul 6;24(13):11143. doi: 10.3390/ijms241311143. Int J Mol Sci. 2023. PMID: 37446319 Free PMC article. Review.
Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma.
Lorenzo-Sanz L, Lopez-Cerda M, da Silva-Diz V, Artés MH, Llop S, Penin RM, Bermejo JO, Gonzalez-Suarez E, Esteller M, Viñals F, Espinosa E, Oliva M, Piulats JM, Martin-Liberal J, Muñoz P. Lorenzo-Sanz L, et al. Among authors: martin liberal j. Nat Commun. 2024 Jun 24;15(1):5352. doi: 10.1038/s41467-024-49718-8. Nat Commun. 2024. PMID: 38914547 Free PMC article.
IGF1R signaling induces epithelial-mesenchymal plasticity via ITGAV in cutaneous carcinoma.
Lopez-Cerda M, Lorenzo-Sanz L, da Silva-Diz V, Llop S, Penin RM, Bermejo JO, de Goeij-de Haas R, Piersma SR, Pham TV, Jimenez CR, Martin-Liberal J, Muñoz P. Lopez-Cerda M, et al. Among authors: martin liberal j. J Exp Clin Cancer Res. 2024 Jul 29;43(1):211. doi: 10.1186/s13046-024-03119-3. J Exp Clin Cancer Res. 2024. PMID: 39075581 Free PMC article.
SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry.
Gonzalez-Cao M, Puertolas T, Martinez-Vila C, Carrera C, Maldonado Seral C, Rodríguez-Jiménez P, Sequero S, Cerezuela-Fuentes P, Feltes Ochoa R, Muñoz E, Antoñanzas Basa M, Martín-Liberal J, Soria A, Francisco Rodriguez Moreno J, Marquez-Rodas I, Lopez Criado P, Luis Manzano J, Lopez-Castro R, Ayala de Miguel P, Villalobos L, Martin Algarra S, Gonzalez-Barrallo I, Boada A, García Castaño A, Puig S, Crespo G, Luna Fra P, Aguayo Zamora C, Feito Rodríguez M, Valles L, Drozdowskyj A, Gardeazabal J, Antonio Fernandez-Morales L, Rodrigo A, Cruz R, Yelamos O, Rubio B, Mujica K, Provencio M, Berrocal A; Spanish Melanoma Group (GEM). Gonzalez-Cao M, et al. Clin Transl Oncol. 2023 Mar;25(3):768-775. doi: 10.1007/s12094-022-02985-7. Epub 2022 Dec 24. Clin Transl Oncol. 2023. PMID: 36566266 Free PMC article.
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours.
Desai J, Fong P, Moreno V, Frentzas S, Meniawy T, Markman B, Voskoboynik M, Rahman T, Budha N, Wu J, Marlow J, Yang S, Calvo E, Martin-Liberal J. Desai J, et al. Br J Cancer. 2023 Apr;128(8):1418-1428. doi: 10.1038/s41416-022-02128-3. Epub 2023 Feb 16. Br J Cancer. 2023. PMID: 36797356 Free PMC article. Clinical Trial.
Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study.
Manzano JL, Martin-Liberal J, Fernández-Morales LA, Benítez G, Medina Martínez J, Quindós M, García-Castaño A, Fernández O, Simo RV, Majem M, Bellido L, Ayala de Miguel P, Campos B, Espinosa E, Macías Cerrolaza JA, Gil-Arnaiz I, Lorente D, Rodriguez-Lescure A, Perez VN, López Castro R, Gramaje MG, Puértolas T, Rodriguez Moreno JF, Espasa Font L, Belaustegui Ferrández G, Cerezuela-Fuentes P. Manzano JL, et al. Among authors: martin liberal j. Melanoma Res. 2023 Oct 1;33(5):388-397. doi: 10.1097/CMR.0000000000000888. Epub 2023 Mar 28. Melanoma Res. 2023. PMID: 36988401 Free PMC article.
Access to melanoma drugs in Spain: a cross-sectional survey.
Gonzalez-Cao M, Puertolas T, Manzano JL, Maldonado C, Yelamos O, Berciano-Guerrero MÁ, Cerezuela P, Martin-Liberal J, Muñoz-Couselo E, Espinosa E, Drozdowskyj A, Berrocal A, Soria A, Marquez-Rodas I, Martin-Algarra S, Quindos M, Puig S; Spanish Melanoma Group (GEM). Gonzalez-Cao M, et al. Among authors: martin liberal j. Clin Transl Oncol. 2024 Oct;26(10):2572-2583. doi: 10.1007/s12094-024-03501-9. Epub 2024 May 16. Clin Transl Oncol. 2024. PMID: 38750345
Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).
Márquez-Rodas I, Álvarez A, Arance A, Valduvieco I, Berciano-Guerrero MÁ, Delgado R, Soria A, Lopez Campos F, Sánchez P, Romero JL, Martin-Liberal J, Lucas A, Díaz-Beveridge R, Conde-Moreno AJ, Álamo de la Gala MDC, García-Castaño A, Prada PJ, González Cao M, Puertas E, Vidal J, Foro P, Aguado de la Rosa C, Corona JA, Cerezuela-Fuentes P, López P, Luna P, Aymar N, Puértolas T, Sanagustín P, Berrocal A. Márquez-Rodas I, et al. Among authors: martin liberal j. Neuro Oncol. 2024 Nov 4;26(11):2074-2083. doi: 10.1093/neuonc/noae116. Neuro Oncol. 2024. PMID: 38946469 Free PMC article. Clinical Trial.
Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis.
Cerezuela-Fuentes P, Gonzalez-Cao M, Puertolas T, Manzano JL, Maldonado C, Yelamos O, Berciano-Guerrero MA, Martin-Liberal J, Muñoz-Couselo E, Espinosa E, Drozdowskyj A, Berrocal A, Soria A, Marquez-Rodas I, Martin-Algarra S, Quindos M, Puig S; Spanish Melanoma Group (GEM). Cerezuela-Fuentes P, et al. Among authors: martin liberal j. Clin Transl Oncol. 2024 Jul 1. doi: 10.1007/s12094-024-03583-5. Online ahead of print. Clin Transl Oncol. 2024. PMID: 38951438
68 results